Catabasis Pharmaceuticals Announces Promotion of Ted Hibben to Chief Business Officer
February 17 2017 - 8:00AM
Business Wire
Catabasis Pharmaceuticals, Inc. (NASDAQ: CATB), a clinical-stage
biopharmaceutical company, today announced the promotion of Ted
Hibben to Chief Business Officer. Mr. Hibben has more than 20 years
of experience in business and corporate development, strategy,
fundraising and M&A. Mr. Hibben joined Catabasis in 2015 and
previously served as Senior Vice President, Corporate
Development.
“Ted has a successful track record of building value with
innovative product platforms, an ideal fit for our SMART linker
platform. The SMART linker platform has already produced product
candidates in multiple disease areas, creating opportunities for
licensing as well as collaboration,” said Jill C. Milne, Chief
Executive Officer of Catabasis. “Ted has been a significant
contributor to the Catabasis executive team and we look forward to
his further leadership in the Chief Business Officer role and his
impact on our corporate strategy.”
Prior to joining Catabasis, Mr. Hibben was Senior Vice
President, Corporate Development at Ensemble Therapeutics, where he
formed four multi-target discovery and development-stage
collaborations with pharmaceutical companies, generating over $1
billion in potential milestone payments for programs emerging from
Ensemble’s macrocycle library platforms. Previously, Mr. Hibben was
Chief Business Officer at Cequent Pharmaceuticals, where he played
an instrumental role in its 2010 merger with MDRNA, Inc. (now
Marina Biotech), and was Vice President, Business Development and
Alliance Management at Coley Pharmaceutical Group, where he sourced
and/or managed nine development alliances and led the sale of Coley
to Pfizer in 2008. Ted holds an MBA from Harvard University and an
AB from Dartmouth College.
About CatabasisAt Catabasis Pharmaceuticals, our mission
is to bring hope and life-changing therapies to patients and their
families. Our SMART (Safely Metabolized And Rationally Targeted)
linker drug discovery platform enables us to engineer molecules
that simultaneously modulate multiple targets in a disease. We are
applying our SMART linker platform to build an internal pipeline of
product candidates for rare diseases and plan to pursue
partnerships to develop additional product candidates. For more
information on the Company's drug discovery platform and pipeline
of drug candidates, please visit www.catabasis.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170217005076/en/
Catabasis Pharmaceuticals, Inc.Andrea Matthews,
617-349-1971amatthews@catabasis.com
Catabasis Pharmaceuticals (NASDAQ:CATB)
Historical Stock Chart
From Aug 2024 to Sep 2024
Catabasis Pharmaceuticals (NASDAQ:CATB)
Historical Stock Chart
From Sep 2023 to Sep 2024